Preparations of isolated liver cells, either freshly prepared or in culture, have been available for many years ; however, because they lack the polarization of the cell in the tissue, their application to the study of processes involved in bile formation has been very limited. The hepatocyte couplet model offers a unique opportunity to study in vitro the intracellular processes involved : not only the physiology and pathophysiology of bile formation, but also the corresponding structural and molecular disturbances underlying different experimental models of cholestasis. In this review we describe the experimental data generated from this model in our laboratory over a period of years, including application of hepatocyte couplets to the study of cytoskeletal changes within the hepatocyte and mechanisms of hepatoprotection in experimentally induced, clinically relevant models of intrahepatic cholestasis.
INTRODUCTION
The liver has many functions, one of the most important of which is the formation and secretion of bile. Bile contains bile acids and lipids, inorganic ions and many metabolic end products (e.g. of haem, steroids, drugs, food additives, environmental chemicals, etc.). Bile formation requires the delivery of these materials to the liver, their extraction into the parenchymal cells (hepatocytes), their modification and movement across the cell, their secretion into the bile canaliculus, their retention in the canaliculus and biliary tract, their onward passage down the bile ducts, their storage and modification in the gall bladder, and their subsequent secretion into the duodenum. Clearly, this physiological function requires the activity of a number of cell types, and the integration and control of a large number of processes. Hepatocellular cholestasis, i.e. the reduction or abolition of bile formation and its consequences, can be due to malfunctions occurring at any of a number of places, and has been studied at a number of levels : the whole organism, the perfused liver and, in vitro, in isolated cell preparations (e.g. parenchymal cells, cholangiocytes, etc.).
Isolated cell preparations of parenchymal cells, both freshly prepared and in culture, have been available for many years, but these preparations lack the polarization needed to study some of the processes of bile formation. In the tissue, hepatocytes are polarized such that they have a sinusoidal or basolateral pole interacting with the blood, and an apical pole where bile is elaborated into the bile canaliculus, a sealed lumen between adjacent hepatocytes. This cellular polarity is determined by : (i) tight junctions sealing the canaliculus ; (ii) differential distribution of the cytoskeleton and associated molecules ; (iii) differential distribution of membrane transporters ; and (iv) differential targeting of specific molecules and vesicular materials [1, 2] .
Freshly isolated hepatocytes prepared by conventional collagenase digestion are normally a preparation of single cells (singlets) which have been separated from their neighbours. As a consequence of the severity of their separation from one another, singlets have lost the differential distribution of transporters, cytoskeletal and junctional elements needed to sustain the biliary pole, and this makes them unsuitable models for the study of the many of the processes of bile formation and cholestasis [3] .
PREPARATION OF HEPATOCYTE COUPLETS
Decreasing the concentration of collagenase used for singlet hepatocyte preparations and the time of exposure to the enzyme results in some hepatocytes failing to separate from one another. These remain together at tight junctions in pairs (couplets or doublets), in triplets or in multiples [2] . Preparations can be obtained that contain 20 % couplets [3, 4] , and further relative enrichment with respect to couplets can be achieved by centrifugal elutriation, yielding preparations containing up to 80 % couplets of high (" 96 %) viability [4] .
The couplets are then resuspended (usually at a concentration of " 1i10&\ml) in a nutritive medium containing suitable additives (e.g. antibiotics, calf serum, hormones, etc.), as required. The processes of isolation cause a degree of damage and the partial redistribution of many cytoskeletal, junctional and transport components, and it is therefore necessary to re-establish both morphological and functional polarity by short-term culture at 37 mC for 4-6 h [3, 5] . Reorganization of the preexisting canaliculus and of material recruited from other locations (particularly hemi-canalicular domains that have lost their adjacent partner) occurs, and the tight junctions seal to form a biliary pole, producing a closed canalicular vacuole [3] . This canalicular vacuole is larger than the original canaliculus, and is sealed rather being open-ended, but it allows the couplet to exhibit the secretory and structural polarity of the hepatocyte in liver tissue. The hepatocyte couplet can therefore be viewed as a primary biliary secretory unit [6] , and better merits the title of a ' mini-liver ' than does the singlet.
Routine couplet preparations contain cells from all zones of the liver lobule ; by modifying the elutriation procedure, enrichment of ' perivenous ' (small) and ' periportal ' (larger) couplets can be obtained, and these show differences in the rate of bile acid secretion and in sensitivities to compounds affecting bile production [7] .
GENERAL APPLICATIONS OF HEPATOCYTE COUPLETS
The most direct use of hepatocyte couplets, therefore, is in the identification of the cell type involved in a particular hepatobiliary activity. When potential choleretic (bile-producing) compounds are investigated, a positive action on accumulation in the hepatocyte canalicular vacuole identifies the involvement of hepatocytes, whereas a negative result places the choleretic effect beyond the liver.
The processes of bile formation can be followed in couplets by viewing, in real time at 37 mC, the filling of the canalicular vacuole, as a model for the secretion of bile into the canalicular lumen. Alterations in the characteristics or kinetics of filling are clearly of relevance in the study of cholestatic situations. In addition, as a polarized cell, the couplet lends itself to the identification and localization of molecular components associated with the formation of bile. Differences in the subcellular distributions of molecular components are also of relevance in the study of cholestatic situations.
There are several techniques available for the study of the filling of the canalicular vacuole. Using visible-light techniques, Nomarski imaging has been used to assess the filling, size and volume of the canalicular vacuole (bile secretion rate). Biliary constituents have been visualized, for some applications, by using dyes or dye-generating molecules, e.g. Ruthenium Red [3] and horseradish peroxidase [8] respectively. The use of fluorescent cholephiles has been most useful in accumulation\transport studies. Fluorescent antibodies or other fluorescent molecules specifically targeted towards different structures relevant to bile formation have been used for localization studies, and have facilitated the use of confocal or image deconvolution techniques.
The time scales of the uptake and secretion of different cholephiles vary, depending on both the efficiency of their respective membrane carriers and their binding to intracellular structures, a critical determinant of the intracellular transit time. Secretion of fluorescent organic anions into the canalicular vacuole is probably dependent upon the activity of the canalicular multispecific organic anion transporter (multidrug-resistant protein 2 ; mrp2). Couplets from TR − \GY rats (transporter minus\ Groningen Yellow rats), which are deficient in mrp2, show defective secretion of carboxydichlorofluorescein diacetate, an mrp2 substrate, although the secretion of bile acids, which mainly use a different transporter, is unaffected [9] . Organic cations, e.g. daunorubicin, are secreted rather slowly into the canaliculus, mainly by the P-glycoproteins mdr1a and mdr1b, and no difference was observed in TR − \GY rats [10] .
Of particular interest for biliary secretion studies are the fluorescently labelled bile acid analogues [1, 11] , which can provide specific information relating to the Use of hepatocyte couplets to investigate cholestasis transport and accumulation of individual bile acids [12, 13] . Indeed, the uptake and canalicular secretion of the cholate and chenodeoxycholate lysyl-fluoresceinlabelled bile acid analogues is rapid, giving a uniform cytoplasmic distribution and detectable fluorescence in the canalicular vacuole within 2 min ; their canalicular accumulation is not affected by colchicine, suggesting that only simple cytoplasmic diffusion, rather than vesicle-mediated transfer, is involved [12, 13] . In contrast, for the ursodeoxycholate analogue, and particularly for the lithocholate analogue, overall transport was slower, was characterized by punctate fluorescence in the cytoplasm and was partially inhibited by inhibitors of vesicle transport [12] . Sulphated bile acids, which probably use mrp2, are poorly secreted in TR − \GY rats [14] .
We have used cholyl-lysyl-fluorescein (CLF) as a general indicator of canalicular function in assays of canalicular vacuole accumulation and retention. In the canalicular vacuolar accumulation (cVA) test, incubation with a low concentration (2 µM) of CLF for 15 min results in all vacuoles capable of being filled becoming clearly visible by epifluorescence microscopy. The number of filled vacuoles is then expressed as a percentage of the total number of vacuoles visible (in controls, this is often as high as 70 %). Cholestatic reagents that affect any of the processes (uptake, transcellular transit, canalicular secretion, vacuolar retention) contributing to the filling of the canalicular vacuole can be studied in relation to their effects in altering the proportion of couplets becoming filled [1, 5] .
The second technique, the canalicular vacuolar retention (cVR) test, uses couplets that have been allowed to accumulate the fluorescent bile acid CLF in their canalicular vacuole, and investigates their ability to retain pre-accumulated CLF. This bypasses the stages of accumulation, transcellular transit and secretion, and therefore gives information on retention, i.e. tight-junctional function, and its dysfunction in some cholestatic situations [8] . A scheme depicting both cVA and cVR tests using CLF is shown in Figure 1 . Figure 2 shows examples of the morphology and use of couplets in the cVA assay with CLF.
STUDIES OF ALTERATIONS IN TIGHT-JUNCTIONAL INTEGRITY USING HEPATOCYTE COUPLETS
As indicated above, tight junctions (zonulae occludens) seal the canalicular lumen between adjacent hepatocytes, thus providing a barrier to the diffusion of biliary solutes between blood and bile. Changes in this permeability barrier under physiological or pathological conditions may occur due to molecular changes resulting in a decrease in the number, density or width of the strands that form the tight-junctional complex, or by dislocation of components, such as occludin, that contribute to its barrier function. These changes are accompanied by leakiness of the paracellular barrier, thus leading to dissipation of the electro-osmotic gradients that drive bile secretion. These functional variations can participate in the regulation of biliary secretory function (if they are reversible and facultatively regulated), or may represent a key pathological mechanism of cholestasis (if they are persistent and severe enough to impair this function irreversibly) (for reviews, see [15] [16] [17] [18] ).
Hepatocyte couplets retain the structural and functional barrier characteristics of the tight junctions that are present in hepatocytes in vivo. Ultrastructural and immunolocalization studies of components of the tightjunctional complex during couplet maturation revealed that, within 4-5 h of culture, couplets re-establish the belt of tight-junctional cell membrane contact, thereby restricting the access of extracellular molecules to the canalicular space and retaining secreted biliary solutes within it [3, 19] . This makes couplets a unique tool for the study of the regulation and impairment of hepatocellular tight-junctional structures in vitro. The lack of extracellular influences in this model makes this approach particularly useful in discriminating pure hepatocellular effects on tight-junctional function from those originating from extracellular sources, such as haemodynamic changes or cross-talk with non-parenchymal liver cells, which are likely to occur particularly when manipulations of signalling pathways are involved.
Using the cVR of CLF test, which assesses the leakage of pre-accumulated vacuole contents as an evaluation of the functional status of the tight-junctional complex (see above), we have shown that changes in junctional permeability occur under a number of pathological and physiological conditions. The cholestatic agents, taurolithocholate [8] , cyclosporin A [8, 20] and β-oestradiol 17-(β-D-glucuronide) (17βEG) [8] , as well as the oxidative-stress-inducers menadione [8, 21] and t-butylhydroperoxide (tBOOH) [8, 22] , all increased tightjunctional permeability, as assessed by cVR of CLF, in a dose-dependent manner.
Likewise, the hormonal modulator vasopressin [8, 23] , [a hormone that induces both an increase in cytosolic Ca# + and protein kinase C (PKC) activation], the PKC activator phorbol 12,13-dibutyrate (PDB), and the Ca# + -elevating compounds A23187 (a Ca# + ionophore) [8, 23, 24] and extracellular ATP [24] all induced acute, dose-dependent changes in tight-junctional permeability in couplets, as assessed by the cVR test. Since analogous changes were seen in the cVA of CLF test, which assesses accumulation in the canalicular vacuole (the net effect of secretion and retention), this suggests that defective retention may have contributed to the decreased canalicular accumulation of CLF that was recorded under such circumstances.
By using antagonists of the PKC-and Ca# + -dependent signalling pathways, a common mechanism to explain the changes in canalicular permeability induced by these agents become apparent, namely activation of classical (Ca# + -dependent) PKC isoforms. In fact, the decreases in cVR of CLF induced by vasopressin, PDB and A23187 were completely prevented both by the PKC inhibitor 1-(5-isoquinolinylsulphonyl)-2-methylpiperazine (H-7) and by the intracellular Ca# + chelator bis-(o-aminophenoxy)ethane-N,N,Nh,Nh-tetra-acetic acid acetoxymethyl ester (BAPTA\AM) [23, 24] , indicating that Ca# + elevations induced by vasopressin can induce leakiness of the paracellular barrier via activation of Ca# + -dependent PKCs.
STUDIES OF CYTOSKELETAL STRUCTURE AND FUNCTION USING HEPATOCYTE COUPLETS
In the early 1980s, in studies using phalloidin as a disrupting agent, changes in actin cytoskeletal integrity in liver tissue were observed, which occurred in parallel with effects on tight-junctional structure and function [25] . A role for changes in actin cytoskeletal organization as an event associated with alterations in canalicular permeability under cholestatic [26] or signallingregulated [27] conditions was not examined until relatively recently, however.
As occurs with tight junctions, couplets reconstitute their actin cytoskeleton within 4-5 h of culture, as a pericanalicular, contractile filamentous (F)-actin belt [3, 19, 27, 28] . In our studies, disorganization of the actin cytoskeleton was assessed either indirectly, by recording one of its most readily apparent consequences, membrane bleb formation, or directly, by assessing the intracellular localization of F-actin, using FITC-labelled phalloidin as a specific probe.
Accompanying the changes observed in the cVR of CLF tests, vasopressin [23] , the PKC activator PDB [23] , and the Ca# + -elevating compounds A23187 and extracellular ATP [24] all induced blebbing and rapid organizational changes in the actin cytoskeleton, with actin being redistributed from the pericanalicular region to the whole cellular body. These changes in actin localization were prevented both by the PKC inhibitor H-7 and by the Ca# + chelator BAPTA\AM [23, 24] . Furthermore, either inhibition of PKC or sequestration of intracellular Ca# + not only prevented, but also rapidly reversed, the impairment in the canalicular accumulation of CLF and bleb formation induced by the Ca# + -elevating compound A23187 (no spontaneous reversal occurred within the time period of the experiments). Taken together, our results strongly suggest that changes in actin distribution are involved in modulatory changes in tight-junctional permeability, via activation of Ca# + -dependent PKC isoforms.
STUDIES ON THE PREVENTION AND REVERSAL OF OXIDATIVE-STRESS-INDUCED HEPATOCANALICULAR DYSFUNCTION USING HEPATOCYTE COUPLETS
In an attempt to apply these new concepts to more clinically relevant situations, and with a view to potential therapeutic use, we analysed, using hepatocyte couplets, whether these signalling pathway modulations are instrumental in preventing and reversing the impairment in canalicular function, tight-junctional permeability and actin cytoskeleton disorganization induced by oxidative stress.
Evidence had been accumulating to indicate that oxidative stress is involved in hepatic malfunction, such as in ischaemia (e.g. during transplantation, or secondary to hepatitis, cirrhosis or tumours [29, 30] ), alcoholism [31] , steatosis (fatty liver) [32] and pathologies associated with the hepatic accumulation of iron (such as hereditary haemochromatosis, porphyria cutanea tarda, thalassaemia major and alcoholic cirrhosis) [33] . Furthermore, oxidative stress is known to elevate intracellular Ca# + [34] and activate PKC [35] [36] [37] in liver cells. For the purpose of our studies, the acute administration of tBOOH or menadione, two inducers of oxidative stress, was used as an experimental tool. tBOOH is metabolized to alkoxy and\or peroxy radicals by the liver [38] , whereas menadione is a redox-cycling quinone whose hepatic metabolism leads to the liberation of reactive oxygen species [39] . mobilization. tBOOH and menadione are oxidative-stress inducers, which cause Ca 2 + elevation and, probably, activation of Ca 2 + -independent PKCs via formation of reactive oxygen species (ROS). PKC activation by any of these mechanisms induces extensive blebbing and redistribution of F-actin from the pericanalicular region to the cell body. This disorganization leads to the opening of the tight junctions, thus permitting the diffusion back into the extracellular fluid of the fluorescent bile salt CLF, used in our studies as a marker of canalicular retention. The pure cholestatic agents taurolithocholate (TLC) and 17βEG impair tight-junctional permeability by a mechanism that seems not to involve disruption of the F-actin cytoskeleton, since no changes in F-actin distribution and/or bleb formation were observed following administration of these compounds at doses that impaired CLF retention.
In support of our working hypothesis that activation of Ca# + -dependent PKC isoforms is involved in changes in canalicular permeability under conditions of oxidative stress, the deleterious effect induced by both pro-oxidant agents on the cVR of CLF was fully prevented by pretreatment with (i) the specific PKC inhibitors H-7 and staurosporine, (ii) the inhibitor of Ca# + -dependent PKCs, Go$ 6976, or (iii) the intracellular Ca# + chelator BAPTA\AM [40] . Furthermore, the permeant cAMP analogue dibutyryl cAMP also prevented the deleterious effects induced by tBOOH or menadione. These beneficial effects of dibutyryl cAMP were blocked by the protein kinase A (PKA) inhibitor KT5720. Since PKA activation is known to negatively regulate PKCdependent signalling pathways in various cell lines [41, 42] , this suggests that PKA may be negatively regulating the PKC-induced changes in canalicular permeability.
Membrane blebbing induced by tBOOH and menadione, used as a preliminary marker of actin cytoskeleton disruption, was also prevented by PKC inhibition, PKA activation or intracellular Ca# + quenching. Cytoskeletal and tight-junctional disruption, and its prevention by PKC inhibition and PKA activation, was confirmed more directly by assessing the distribution of F-actin and the tight-junctional proteins occludin and zonula occludens-1.
PKC inhibition and PKA activation not only prevented, but also fully reversed within 50-60 min, both the decrease in the percentage of couplets accumulating CLF and the increased blebbing induced by tBOOH. Taken together, these results suggest that oxidative stress affects paracellular permeability mainly through a Ca# + -dependent, PKC-mediated mechanism, and that inhibition of Ca# + -dependent PKCs, or activation of PKA, is instrumental in both preventing and reversing these harmful effects. Once again, actin cytoskeletal integrity seems to play a crucial role in the observed effects.
Whereas F-actin cytoskeletal disruption is readily apparent in the changes in canalicular permeability that occur in oxidative-stress-induced cholestasis, the participation of this pathogenetic mechanism in other cholestatic conditions is less clear. For example, extensive impairment of the retentive properties of the couplet canalicular vacuoles, as assessed by the cVR of CLF, occurs at concentrations of taurolithocholic acid as low as 1 µM [8] , whereas neither blebbing nor changes in F-actin were detected even at concentrations as high as 2.5 µM. Likewise, 17βEG affected the cVR of CLF at concentrations of 75 µM and above, whereas no bleb formation was apparent, even at a concentration of 400 µM. Figure 3 shows the mechanisms involved in actincytoskeleton-associated changes in tight-junctional permeability, the involvement of signalling pathways in this phenomenon, and the putative intracellular targets of pure cholestatic compounds known to affect paracellular permeability in hepatocyte couplets.
STUDIES OF HEPATOPROTECTION AGAINST TAUROLITHOCHOLATE-INDUCED CHOLESTASIS USING HEPATOCYTE COUPLETS
Lithocholic acid and its amidated conjugate, taurolithocholate, are naturally occurring hydrophobic monohydroxy bile acids. They have been linked with the pathogenesis of impaired bile flow in several chronic cholestatic liver diseases [43] and in cholestasis induced by total parenteral nutrition.
At the level of the hepatocyte, taurolithocholate may decrease the fluidity of the canalicular membrane and cause an accumulation of cholesterol within the membrane, thus decreasing the phospholipid\cholesterol ratio [44] , inhibiting Na + \K + -ATPase, a key driving force of the bile-salt-independent bile flow [45] , and increasing the leakiness of the paracellular barrier [46] . In hepatocyte couplets, taurolithocholate induces inhibition of the cVA of CLF in a dose-dependent fashion [47] .
By studying different therapeutic strategies, we have shown that three hepatoprotective agents, tauroursodeoxycholate (TUDC), S-adenosyl-L-methionine (SAMe), and the active component of silymarin, silibinin, were able to prevent and\or reverse this cholestatic effect.
Ursodeoxycholate is a naturally occurring hydrophilic bile acid which, in humans, improves objective markers of cholestasis, such as liver function tests and liver histology [48] . Its hepatoprotective properties, initially linked to replacement of toxic, endogenous bile acids or inhibition of their intestinal uptake, have been studied thoroughly over the last decade. It has now been found that ursodeoxycholate may prevent damage to cytoskeletal structures and decreases in membrane fluidity [49] . It may also inhibit the formation of cholestatic, glucuronidated metabolites of oestradiol in the rat model of ethinyl oestradiol-induced cholestasis [50] . It has been postulated that the hepatoprotective effects of TUDC may be mediated by activation of intracellular signalling pathways. Beuers et al. [51] demonstrated that TUDC increases intracellular Ca# + by depleting Ins(1,4,5)P $ -sensitive Ca# + stores, and by increasing the influx of Ca# + .
Increased levels of cytosolic Ca# + stimulate the translocation of Ca# + -dependent PKC into the membrane, with subsequent activation of apical exocytosis [51, 52] .
This hypothesis has been supported by our most recent study on hepatocyte couplets. We observed a significant impairment of the hepatoprotective effect of TUDC in taurolithocholate-induced cholestasis by the Ca# + chelator BAPTA\AM, and by the two PKC inhibitors H-7 and staurosporine [53] . The protective effect of TUDC was not affected by the PKA inhibitor KT2750, which suggests that a Ca# + -stimulated, PKCdependent (but not PKA-dependent) pathway may be involved in the beneficial effect of TUDC.
In an earlier section, we indicated that activation of PKC by phorbol esters or by a sustained large increase in Ca# + concentration induced by the ionophore A23187 or by oxidative stress could induce hepatocanalicular damage. Although the above results relating to hepatoprotection by TUDC involving a Ca# + -stimulated PKC would therefore appear to be in contradiction to this, differences in the magnitude and longevity of both the Ca# + increase and the PKC activation, as well as the isoform(s) of PKC activated, may account for this apparent discrepancy. Thus it is known that the increase in Ca# + concentration induced by A23187 [54] or by oxidative stress [55] is long-lasting and is greater in magnitude than that induced by TUDC, which produces its effects via smaller, modulatory changes in Ca# + concentration [51] . In addition, although PKC appears to bring about both damaging and protective effects, these differential effects may be due to different PKC isoforms, since phorbol esters exert a pan-stimulatory effect on most PKC isoforms, whereas TUDC appears to exert its effect on α-PKC alone. The resolution of such dilemmas will become clearer with the advent of further tools that permit the study of the effects of such individual PKC isoforms.
Another hepatoprotective agent that has been used in studies with hepatocyte couplets is SAMe. This substance is a naturally occurring agent which is a major donor of methyl groups and is also an intermediary metabolite in the synthesis of cysteine and glutathione. Transmethylation employing SAMe is an important mechanism used by liver cells in the detoxification of several toxins. SAMe can also act as a precursor for liver glutathione through the trans-sulphuration route ; glutathione plays a key role in maintaining the normal redox potential in the liver. In some chronic liver diseases a deficiency of the enzyme SAMe synthetase has been demonstrated, which causes subsequent dysfunction in detoxifying processes. It has also been suggested that SAMe may increase the sulphation of toxic metabolites in ethinyl oestradiol-induced cholestasis [56] .
Both TUDC and SAMe were able to partially protect against and reverse taurolithocholate-induced cholestasis in the hepatocyte couplet model [47] . This effect was The location of bsep was determined using a fluorescent antibody technique. Under control conditions, bsep is localized to the paracanalicular region. After exposure to taurolithocholate (TLC), bsep is redistributed away from the canaliculus into the body of the cell.
observed both in severe cholestasis (with a decrease in the cVA of CLF of approx. 80 %) and in moderate cholestasis (decrease in the cVA of CLF of approx. 50 %). When the two compounds were used simultaneously, their effect was additive, which suggests the involvement of independent protective mechanisms, leading to cooperative effects of the two hepatoprotectants against taurolithocholate-induced cholestasis. It is possible that SAMe, being a precursor of a sulphate group, may facilitate sulphation of taurolithocholate at position 3 in the steroid ring, making it much more soluble and noncholestatic. As a result, taurolithocholate could be eliminated from the hepatocyte not only via the dedicated canalicular transporter, the bile salt export pump (bsep), but also as a sulphated or glucuronidated metabolite, utilizing another canalicular transporter, mrp2. In addition, the soluble, sulphated taurolithocholate may also be regurgitated back to the blood and excreted in the urine.
Hepatoprotection against the action of taurolithocholate is also associated with an increased presence of the transporter, mrp2, in the canalicular membrane of the hepatocyte. Appropriate insertion of transporters into the apical membrane has been shown to require an intact actin network [57] , and we have observed that vesiclemediated membrane re-insertion of canalicular transporters internalized following couplet isolation requires recovery of the integrity of the actin cytoskeleton [27] . It seems plausible that redistribution of the F-actin cytoskeleton from the pericanalicular area to the cell body induced by taurolithocholate may be a critical factor in explaining the loss of canalicular transporters induced by this agent. Furthermore, the finding that TUDC partially protected against disruption of the F-actin cytoskeleton and also, simultaneously, prevented redistribution of mrp2 transporters strongly suggests a causal relationship. By assessing the ability of a number of cholestatic compounds, including taurolithocholate, to produce changes in the F-actin cytoskeleton, Thibault et al. [26] proposed that a link exists between cholestasis and changes in the actin cytoskeleton. In a further study [58] , this group showed that TUDC prevented the changes in F-actin induced by taurolithocholate when the hepatoprotective bile salt was added to the medium together with taurolithocholate. Our results have confirmed and extended these early studies.
The molecular details of the mechanism by which TUDC protects against F-actin disruption, however, remain elusive, and elucidation will require further work. However, dose-dependency studies on the effects of taurolithocholate on F-actin cytoskeleton integrity caution against assigning an indispensable role to F-actin disarray in taurolithocholate-induced cholestasis, since taurolithocholate, at low doses able to reduce by half the cVA of CLF and to induce a marked redistribution of the canalicular bile salt transporter, bsep, had no detectable effect on actin localization (Figure 4 ). Therefore additional mechanisms by which taurolithocholate induces the displacement of canalicular transporters, or by which TUDC protects against this relocalization, need to be explored. The arrest of the microtubule-mediated vesicular pathway by taurolithocholate [58, 59] , which may impair the sorting of canalicular transporters, is a candidate mechanism as it is also prevented by TUDC [60] .
In a recent study, we evaluated the effects of another hepatoprotective agent, silibinin, on the taurolithocholate-induced impairment of canalicular function in hepatocyte couplets. Silibinin is the major, active component of silymarin, a purified extract from the milk thistle Silybum marianum (L.) Gaertn, which has been shown to protect experimental animals from various hepatotoxins, including carbon tetrachloride, acetaminophen and phalloidin [61] . Like SAMe and TUDC, silibinin could counteract both taurolithocholate-induced impairment of the cVA of CLF in hepatocyte couplets and the displacement of the canalicular transporters induced by taurolithocholate (P. Milkiewicz, M. G. Roma, E. Elias and R. Coleman, unpublished work).
STUDIES OF HEPATOPROTECTION AGAINST 17βEG-INDUCED CHOLESTASIS USING HEPATOCYTE COUPLETS
17βEG is the most cholestatic metabolite of oestradiol. Impairment of bile flow caused by this compound has been associated with its deleterious effects on bile salt excretion [62] and bile-salt-independent bile flow [63] , increased permeability of tight junctions [62, 64] , decreased fluidity of the sinusoidal membrane and inhibition of Figure 5 Mechanisms by which the anti-cholestatic compounds SAMe and TUDC may exert their beneficial effects on taurolithocholate-and 17βEG-induced cholestasis in isolated rat hepatocyte couplets Left cell : both taurolithocholate (TLC) and CLF, a fluorescent bile salt used to assess hepatocanalicular function, are taken up by the basolateral bile salt transporters, ntcp, and (to a lesser extent) by the organic anion (OA − ) transporter, oatp. 17βEG is most probably taken up only via oatp. Transfer of CLF into the canalicular vacuole, which is mediated by the ATP-dependent transporter bsep, is impaired by both taurolithocholate and 17βEG. SAMe may prevent taurolithocholate and 17βEG from inducing their cholestatic effects by promoting their sulphation (TLC-S and 17βEG-S), thus rendering them non-cholestatic. Right cell : the anti-cholestatic effect of TUDC seems to involve modulation of signal transduction pathways. TUDC increases the cytosolic Ca 2 + concentration ([Ca 2 + ] cyt ) by stimulating both Ca 2 + release from microsomal, inositol 1,4,5-trisphosphate (IP 3 )-sensitive stores via an IP 3 -independent pathway and Ca 2 + influx from extracellular sources via Ni 2 + -sensitive channels, which leads to the activation of Ca 2 + -dependent PKC isoforms. Activation of Ca 2 + -and PKC-dependent pathways by TUDC may counteract the scattering of canalicular transporters induced by taurolithocholate and 17βEG, by stimulating their recruitment from the subapical compartment (SAC) and re-insertion into the canalicular membrane.
Na + \K + -ATPase [65] . In a similar fashion to taurolithocholate, 17βEG induces rapid, dose-dependent cholestasis in hepatocyte couplets, as evaluated by a decrease in the cVA of CLF [66, 67] . Protection against this effect, as well as its reversal, has been observed with SAMe and TUDC [66] , and with silibinin [67] . However, unlike in taurolithocholate-induced cholestasis, the beneficial effects of the two hepatoprotectants in 17βEG-induced cholestasis were not additive. Interestingly, the protective effect of SAMe was abolished by dehydroepiandrosterone, a competitive substrate for sulphotransferases involved in intracellular sulphation. This finding supports the contention that an important protective effect of SAMe involves its role as a precursor of the sulphate group, facilitating the sulphation of 17βEG on position 3, and thereby abolishing the cholestatic effect of 17βEG.
At the concentrations used in our experiments with hepatocyte couplets, 17βEG had no effect on the structures of the pericanalicular cytoskeleton. Thus the protective effect of TUDC against 17βEG-induced cholestasis cannot be associated with its role in maintaining cytoskeletal integrity. The lack of an additive effect of SAMe and TUDC in 17βEG-induced cholestasis suggests that the two compounds may act via an overlapping mechanisms. It has been postulated that 17βEG may exert a cis-inhibitory effect on the canalicular transporter mdr1 [68] . This hypothesis was based on the fact that substrates for mdr1 competitively protected against 17βEG-induced cholestasis. In keeping with this, micelleforming bile salts such as TUDC, but not nonmicelle-forming bile salts such as dehydrocholate, were able to reverse an impairment of bile flow induced by 17βEG. TUDC may be involved in the intracanalicular solubilization of 17βEG into mixed micelles, thus preventing the interaction of 17βEG with the putative effector of its cholestatic effect. However, 17βEG may also exert a direct inhibitory effect on other canalicular transporters, as demonstrated by ourselves [69] and others [70] for mrp2, as well as for bsep [71] .
A scheme outlining the main mechanisms involved in the anti-cholestatic effects of SAMe and TUDC in taurolithocholate-and 17βEG-induced cholestasis are depicted in Figure 5 . Further elucidation of the signalling pathways involved in the physiology and pathophysiology of bile secretion and the putative mechanisms of action of anti-cholestatic agents should be possible with appropriate experimental design utilizing the hepatocyte couplet model. The ability to visualize bile formation and retention within canalicular vacuoles at the same time as monitoring the modulatory processes that control it make this easily accessible, structurally organized, basic unit of hepatocyte function an attractive model for further investigation.
